Research progress in Shenxian Shengmai oral liquid in treating bradycardia
Author:
Affiliation:

(1. Department of Clinical Medicine, Medical College of Yangzhou University, Yangzhou 225009, Jiangsu Province, China;2. Department of Cardiology, Northern Jiangsu People′s Hospital, Yangzhou 225001, Jiangsu Province, China)

Clc Number:

R541.7

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Shenxian Shengmai (SXSM) oral liquid is a Chinese patent medicine with proven curative efficacy and safety. Evidence from modern pharmacological studies with various animals and cells show that SXSM can accelerate the heart rate and improve the clinical symptoms of patients with bradycardia by increasing the concentration of cyclic adenosine monophosphate in cells, promoting the opening of calcium channels, improving the degree of pathological damage, delaying fibrosis of sinus node in patients with sick sinus syndrome, increasing If current and regulating gene expression. A large number of clinical studies have shown that SXSM has a better efficacy on heart rate improvement than other traditional Chinese patent medicines and western medicines that increase heart rate.

    Reference
    Related
    Cited by
Get Citation
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:June 13,2020
  • Revised:
  • Adopted:
  • Online: March 29,2021
  • Published: